Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy
نویسندگان
چکیده
منابع مشابه
Bispecific antibodies engage T cells for antitumor immunotherapy.
INTRODUCTION Although considerable evidence supports the hypothesis that T cells play a critical role in the immune response against cancer, the ability to mount and sustain tumor-specific cellular responses in vivo remains a challenge. A strategy that harnesses the cytotoxic advantage of T cell therapy is the use of bispecific antibodies designed to engage and activate endogenous polyclonal T ...
متن کاملCryogel-supported stem cell factory for customized sustained release of bispecific antibodies for cancer immunotherapy
Combining stem cells with biomaterial scaffolds provides a promising strategy for the development of drug delivery systems. Here we propose an innovative immunotherapeutic organoid by housing human mesenchymal stromal cells (MSCs), gene-modified for the secretion of an anti-CD33-anti-CD3 bispecific antibody (bsAb), in a small biocompatible star-shaped poly(ethylene glycol)-heparin cryogel scaff...
متن کاملImmunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous Melanoma
In the last few years, there has been a twist in cancer treatment toward immunotherapy thanks to the impressive results seen in advanced patients from several tumor pathologies. Cutaneous melanoma is a highly mutated and immunogenic tumor that has been a test field for the development of immunotherapy. However, there is still a way on the road to achieving complete and long-lasting responses in...
متن کاملBispecific Antibodies: Bright Way for Cancer Therapeutics
Antibody based cancer therapeutics show great beneficial to more and more patients and the antibody drug market is growing fast. As Removab® approved in 2009 and BlincytoTM approved in 2014, bispecific antibodies with combination of two antigen binding specificities shed new light on antibody based cancer therapeutics especially when new technologies for engineering and manufacturing are availa...
متن کاملBispecific antibodies targeting cancer cells.
In recent years, antibody therapy has become a new treatment modality for tumour patients, although the majority of responses are only partial and not long lasting. Based on evidence that effector-cell-mediated mechanisms significantly contribute to antibody efficacy in vivo, several approaches are currently pursued to improve the interaction between Fc receptor-expressing effector cells and tu...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Cancer Research
سال: 2021
ISSN: 1078-0432,1557-3265
DOI: 10.1158/1078-0432.ccr-20-3770